Searchable abstracts of presentations at key conferences in endocrinology

ea0041gp28 | Adrenal (2) | ECE2016

Restoring the circadian cortisol rhythm with metyrapone in patients with adrenal incidentalomas and subclinical hypercortisolism reduces IL6 levels

Debono Miguel , Harrison Robert , Chadarevian Rita , Gueroult Carole , Abitbol Jean-Louis , Newell-Price John

Introduction: Patients with adrenal incidentalomas and sub-clinical Cushing’s (SCH) have increased cardiovascular events and mortality. We hypothesised that these patients have a disturbed cortisol rhythm amenable to being restored to normal by using timed short-acting cortisol synthesis blockade, and that this may have a positive effect on IL6 levels.Methods: In a phase 1, prospective study (Eudract No. 2012-002586-35) we recruited eight patients w...

ea0032p516 | Endocrine tumours and neoplasia | ECE2013

Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma

Kerkhofs Thomas , Baudin Eric , Terzolo Massimo , Allolio Bruno , Chadarevian Rita , Leboulleux Sophie , Mantero Franco , Haak Harm , Fassnacht Martin

Introduction: Current medical treatment of adrenocortical carcinoma (ACC) is based on mitotane alone or in combination with cytotoxic chemotherapy. However, very little is known about the pharmacokinetic properties of mitotane and dosing schedules are based on clinical experience only. The aim of this study was to investigate the relationship between mitotane dose and plasma concentration comparing two pre-defined treatment regimens. Secondary objectives were to evaluate safet...

ea0022p424 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Serum concentration of o,p’DDD (mitotane), o,p’DDA and o,p’DDE as predictors of tumour response in adrenocortical carcinoma: results of a retrospective European Network for the Study of Adrenal Tumors (ENS@T) multicentre study

Hermsen Ilse , Fassnacht Martin , Terzolo Massimo , Houterman Saskia , Hartigh Jan den , Leboulleux Sophie , Daffara Fulvia , Allolio Bruno , Berruti Alfredo , Chadarevian Rita , Haak Harm , Baudin Eric

Introduction: O,p’DDD is the drug of choice for patients with adrenocortical carcinoma (ACC). Monitoring o,p’DDD serum level has been proposed as predictor of tumour response. Measurement of o,p’DDD metabolites involved in the active pathway may provide an improved prediction of o,p’DDD activity. The objective of our study was to (1)to confirm the currently used threshold o,p’DDD serum level of 14mg/l for achieving a tumour response and (2)compare the ...